Literature DB >> 26349079

Self-Assembling Monomeric Nucleoside Molecular Nanoparticles Loaded with 5-FU Enhancing Therapeutic Efficacy against Oral Cancer.

Hang Zhao1,2, Hui Feng1,3, Dongjuan Liu1, Jiang Liu1,2, Ning Ji1, Fangman Chen1, Xiaobo Luo1, Yu Zhou1, Hongxia Dan1, Xin Zeng1, Jing Li1, Congkui Sun1, Jinyu Meng1, Xiaojie Ju4, Min Zhou1, Hanshuo Yang5, Longjiang Li1, Xinhua Liang1, Liangyin Chu4, Lu Jiang1, Yang He2, Qianming Chen1.   

Abstract

Conventional oligonucleotide based drug delivery systems suffer from lengthy synthetic protocols, high cost, and poor chemical or enzymatic stability under certain circumstances. Canonical free individual nucleosides cannot form stable nanostructures in aqueous solution as drug vehicles. Here, we report the development of a monomeric self-assembled nucleoside nanoparticle (SNNP) into an efficient drug delivery system which has currently no parallel in such field. This was achieved using a l-configurational pyrimido[4,5-d]pyrimidine nucleoside building block that can form robust discrete nanoparticles in just one step with water as the sole solvent. Its high biocompatibility and low toxicity was demonstrated in vitro and in vivo. In mouse xenograft model of oral squamous cell carcinoma (OSCC), SNNP loaded with 5-fluoro-uracile (5-FU-SNNP) remarkably retarded the tumor growth compared with free 5-FU, albeit SNNP alone showed no antitumor effect. The stability in blood circulation and the effective concentration of 5-FU in tumor tissue were increased upon the loading with SNNP. TUNEL and immunohistochemistry analyses further indicated that the superior in vivo antitumor efficacy of 5-FU-SNNP compared to free 5-FU was associated with an enhanced degree of inhibition of cell proliferation and stimulation of cell apoptosis. Furthermore, SNNP alleviated the toxic side effects of 5-FU. These findings suggested that when loaded with SNNP, 5-FU has better antitumor efficacy and lower side effects, indicating that SNNP can efficiently act as a readily accessible, robust, biocompatible and low-toxic nanobiomaterial which may find wide therapeutic applications clinically in the future.

Entities:  

Keywords:  5-FU; J-TA ribonucleoside nanoparticles; cancer therapy; drug delivery systems; self-assembled

Mesh:

Substances:

Year:  2015        PMID: 26349079     DOI: 10.1021/acsnano.5b04520

Source DB:  PubMed          Journal:  ACS Nano        ISSN: 1936-0851            Impact factor:   15.881


  6 in total

Review 1.  Nanotechnology in oral cancer: A comprehensive review.

Authors:  Monika Poonia; Karthikeyan Ramalingam; Sandeep Goyal; Supreet Kaur Sidhu
Journal:  J Oral Maxillofac Pathol       Date:  2017 Sep-Dec

2.  Gelatinase-sensitive nanoparticles loaded with photosensitizer and STAT3 inhibitor for cancer photothermal therapy and immunotherapy.

Authors:  Lin-Lin Bu; Han-Qi Wang; Yuanwei Pan; Lei Chen; Hao Wu; Xianjia Wu; Chenchen Zhao; Lang Rao; Bing Liu; Zhi-Jun Sun
Journal:  J Nanobiotechnology       Date:  2021-11-21       Impact factor: 10.435

Review 3.  New strategies against drug resistance to herpes simplex virus.

Authors:  Yu-Chen Jiang; Hui Feng; Yu-Chun Lin; Xiu-Rong Guo
Journal:  Int J Oral Sci       Date:  2016-03-30       Impact factor: 6.344

4.  Enhanced antineoplastic/therapeutic efficacy using 5-fluorouracil-loaded calcium phosphate nanoparticles.

Authors:  Shanid Mohiyuddin; Saba Naqvi; Gopinath Packirisamy
Journal:  Beilstein J Nanotechnol       Date:  2018-09-20       Impact factor: 3.649

5.  Efficient miRNA Inhibitor Delivery with Graphene Oxide-Polyethylenimine to Inhibit Oral Squamous Cell Carcinoma.

Authors:  Lingling Ou; Ting Sun; Minyi Liu; Ye Zhang; Zhiying Zhou; Xiaozhen Zhan; Lihong Lu; Qingtong Zhao; Renfa Lai; Longquan Shao
Journal:  Int J Nanomedicine       Date:  2020-03-09

Review 6.  Insights into Nanomedicine for Immunotherapeutics in Squamous Cell Carcinoma of the head and neck.

Authors:  Qiang Xu; Meiyu Fang; Jing Zhu; Haoru Dong; Jun Cao; Lin Yan; Fransisca Leonard; Felix Oppel; Holger Sudhoff; Andreas M Kaufmann; Andreas E Albers; Xu Qian
Journal:  Int J Biol Sci       Date:  2020-07-19       Impact factor: 6.580

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.